Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes

ILAR Journal

Volumn 47, Issue 3, 2006, Pages 225-233

  Matveyenko, Aleksey V ^a   Butler, Peter C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid; Apoptosis; Beta cell; Diabetes; h IAPP transgenic mouse; HIP rat; Islet amyloid polypeptide (IAPP)

Indexed keywords

AMYLIN; GLUCOSE; INSULIN; OLIGOMER;

ANIMAL MODEL; APOPTOSIS; ARTICLE; BREEDING; CAT; DIABETOGENESIS; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LONGITUDINAL STUDY; MONKEY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOLOGY; PATHOPHYSIOLOGY; PRIMATE; PROTEIN EXPRESSION; RAT; RODENT; TRANSGENE; TRANSGENIC ANIMAL;

PRIMATES; RODENTIA;

EID: 33745586536     PISSN: 10842020     EISSN: None     Source Type: Journal    
DOI: 10.1093/ilar.47.3.225     Document Type: Article

References (66)

1. Ahren B, Oosterwijk C, Lips CJ, Hoppener JW. 1998. Transgenic over-expression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice. Diabetologia 41:1374-1380.
2. Baetens D, Stefan Y, Ravazzola M, Malaisse-Lagae F, Coleman DL, Orci L. 1978. Alteration of islet cell populations in spontaneously diabetic mice. Diabetes 27:1-7.
3. Betsholtz C, Svensson V, Rorsman F, Engstrom U, Westermark GT, Wilander E, Johnson K, Westermark P. 1989. Islet amyloid polypeptide (IAPP): cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. Exp Cell Res 183:484-493.
4. Bock T, Pakkenberg B, Buschard K. 2003. Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 52:1716-1722.
5. Boscaro M, Barzon L, Fallo F, Sonino N. 2001. Cushing's syndrome. Lancet 357:783-791.
6. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC. 2004. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): A new model for type 2 diabetes. Diabetes 53:1509-1516.
7. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. 2003a. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110.
8. Butler AE, Janson J, Soeller WC, Butler PC. 2003b. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: Evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52:2304-2314.
9. Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, Chang JK, Rizza RA. 1990. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39:752-756.
10. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. 1994. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17:961-969.
11. Chen H, Charlat O, Turtaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey NK, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. 1996. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell 84:491-495.
12. Cnop M, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG. 2001. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 50:1771-1777.
13. Couce M, Kane LA, O'Brien TD, Charlesworth J, Soeller W, McNeish J, Kreutter D, Roche P, Butler PC. 1996. Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes 45:1094-1101.
14. De Koning EJ, Hoppener JW, Verbeek JS, Oosterwijk C, Van Hulst KL, Baker CA, Lips CJ, Morris JF, Clark A. 1994. Human islet amyloid polypeptide accumulates at similar sites in islets of transgenic mice and humans. Diabetes 43:640-644.
15. Donath MY, Gross DJ, Cerase E, Kaiser N. 1999. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738-744.
16. Edvell A, Lindstrom P. 1999. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology 140:778-783.
17. Fagot-Campagna A, Saaddine JB, Glegal KM, Beckles, GL. 2001. Diabetes, impaired fasting glucose, and elevated HbA1c in U.S. adolescents: The Third National Health and Nutrition Examination Survey. Diabetes Care 24:834-837.
18. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, Buckingham RE. 2001. Beta-cell mass dynamics in Zucker diabetic fatty rats: Rosiglitazone prevents the rise in net cell death. Diabetes 50:1021-1029.
19. Fogar P, Pasquali C, Basso D, Sperti C, Panozzo MP, Tessari G, D'Angeli F, Del Favero G, Plebani M. 1994. Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res 14:2827-2830.
20. Frisbie JH. 2005. Diabetes mellitus and preventable spinal cord injury. J Spinal Cord Med 28:60-63.
21. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. 1986. Insulin resistance in acromegaly: Defects in both hepatic and extrahepatic insulin action. Am J Physiol 250:E269-E273.
22. Harmon JS, Gleason CE, Tanaka Y, Poitout V, Robertson RP. 2001. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 50:2481-2486.
23. Hoppener JW, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JH, Vroom TM, Ahren B, Lips CJ. 1999. Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: Pathogenesis of diabetes in a mouse model. Diabetologia 42:427-434.
24. Howard CF Jr. 1986. Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29:301-306.
25. Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Coop M, Prigeon RL, Kahn SE. 2003. Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52:372-379.
26. Hull RL, Watts MR, Kodama K, Shen ZP, Utzschneider KM, Carr DB, Vidal J, Kahn SE. 2005. Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice. Am J Physiol Endocrinol Metab 289:E703-E709.
27. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. 1999. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491-498.
28. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC. 1996. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:7283-7288.
29. Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K. 2005. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/ db mice. Am J Physiol Endocrinol Metab 288:E510-E518.
30. King H, Aubert RE, Herman WH. 1998. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431.
31. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. 1994. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 91:10878-10882.
32. Leighton B, Cooper GJ. 1990. The role of amylin in the insulin resistance of non-insulin-dependent diabetes mellitus. Trends Biochem Sci 15: 295-299.
33. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. 1994. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368:756-760.
34. Luft R, Cerasi E, Hamberger CA. 1967. Studies on the pathogenesis of diabetes in acromegaly. Acta Endocrinol (Copenh) 56:593-607.
35. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY. 2002. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851-860.
36. Medarova Z, Bonner-Weir S, Lipes M, Moore A. 2005. Imaging beta-cell death with a near-infrared probe. Diabetes 54:1780-1788.
37. Movassat J, Saulnier C, Serradas P, Portha B. 1997. Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia 40:916-925.
38. O'Brien TD, Butler AE, Roche PC, Johnson KH, Butler PC. 1994. Islet amyloid polypeptide in human insulinomas: Evidence for intracellular amyloidogenesis. Diabetes 43:329-336.
39. O'Brien TD, Butler PC, Westermark P, Johnson KH. 1993. Islet amyloid polypeptide: A review of its biology and potential roles in the pathogenesis of diabetes mellitus. Vet Pathol 30:317-332.
40. Ohsawa H, Kanatsuka A, Yamaguchi T, Makino H, Yoshida S. 1989. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 160:961-967.
41. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. 1995. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540-543.
42. Perseghin G, Caumo A, Arcelloni C, Benedini S, Lanzi R, Pagliato E, Sereni LP, Testolin G, Battezzati A, Comi G, Comola M, Luzi L. 2003. Contribution of abnormal insulin secretion and insulin resistance to the pathogenesis of type 2 diabetes in myotonic dystrophy. Diabetes Care 26:2112-2118.
43. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, Hess JF. 1996. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13:18-19.
44. Picarel-Blanchot F, Berthelier C, Bailbe D, Portha B. 1996. Impaired insulin secretion and excessive hepatic glucose production are both early events in the diabetic GK rat. Am J Physiol 271:E755-E762.
45. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, Polonsky KS. 1998. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47:358-364.
46. Portha B, Giroix MH, Serradas P, Gangnerau MN, Movassat J, Rajas F, Bailbe D, Plachot C, Mithieux G, Marie JC. 2001. Beta-cell function and viability in the spontaneously diabetic GK rat: Information from the GK/ Par colony. Diabetes 50(Suppl 1):S89-S93.
47. Ritzel RA, Butler PC. 2003. Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 52:1701-1708.
48. Rosenbloom AL, Joe JR, Young RS, Winter WE. 1999. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22:345-354.
49. Sando H, Lee YS, Iwamoto Y, Ikeuchi M, Kosaka K. 1980. Isoproterenol-stimulated C-peptide and insulin secretion in diabetic and nonobese normal subjects: Decreased hepatic extraction of endogenous insulin in diabetes. J Clin Endocrinol Metab 51:1143-1149.
50. Shafrir E, Gutman A. 1993. Psammomys obesus of the Jerusalem colony: A model for nutritionally induced, non-insulin-dependent diabetes. J Basic Clin Physiol Pharmacol 4:83-99.
51. Shafrir E, Ziv E, Mosthaf L. 1999. Nutritionally induced insulin resistance and receptor defect leading to beta-cell failure in animal models. Ann N Y Acad Sci 892:223-246.
52. Shimabukuro M, Zhou YT, Levi M, Unger RH. 1998. Fatty acid-induced beta cell apoptosis: A link between obesity and diabetes. Proc Natl Acad Sci U S A 95:2498-2502.
53. Shimizu M, Hayashi T, Saitoh Y, Ohta K, Itoh H. 1990. Postmortem autolysis in the pancreas: Multivariate statistical study. The influence of clinicopathological conditions. Pancreas 5:91-94.
54. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J. 1996. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19: 998-1000.
55. Soeller WC, Janson J, Hart SE, Parker JC, Carty MD, Stevenson RW, Kreutter DK, Butler PC. 1998. Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. Diabetes 47:743-750.
56. Tedstone AE, Nezzer T, Hughes SJ, Clark A, Matthews DR. 1990. The effect of islet amyloid polypeptide (amylin) and calcitonin gene-related peptide on glucose removal in the anaesthetized rat and on insulin secretion from rat pancreatic islets in vitro. Biosci Rep 10:339-345.
57. Tokuyama T, Yagui K, Yamaguchi T, Huang CI, Kuramoto N, Shimada F, Miyazaki J, Horie H, Saito Y, Makino H, Kanatsuka A. 1997. Expression of human islet amyloid polypeptide/amylin impairs insulin secretion in mouse pancreatic beta cells. Metabolism 46:1044-1051.
58. Tomita T, Doull V, Pollock HG, Krizsan D. 1992. Pancreatic islets of obese hyperglycemic mice (ob/ob). Pancreas 7:367-375.
59. UKPDS [UK Prospective Diabetes Study Group]. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853.
60. Unger RH. 1995. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: Genetic and clinical implications. Diabetes 44:863-870.
61. Wang F, Hull RL, Vidal J, Cnop M, Kahn SE. 2001. Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:2514-2520.
62. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. 1984. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318-1328.
63. Warne DK, Charles MA, Hanson RL, Jacobsson LT, McCance DR, Knowler WC, Pettitt DJ. 1995. Comparison of body size measurements as predictors of NIDDM in Pima Indians. Diabetes Care 18:435-439.
64. Wei M, Gaskill SP, Haffner SM, Stern MP. 1998. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: The San Antonio Heart Study. Diabetes Care 21:1167-1172.
65. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C. 1990. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036-5040.
66. Yagui K, Yamaguchi T, Kanatsuka A, Shimada F, Huang CI, Tokuyama Y, Ohsawa H, Yamamura K, Miyazaki J, Mikata A, Yoshida S, Makino H. 1995. Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin. Eur J Endocrinol 132:487-496.